Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

1.62
-0.0700-4.14%
Pre-market: 1.650.0300+1.85%04:00 EDT
Volume:800.95K
Turnover:1.30M
Market Cap:36.71M
PE:-0.12
High:1.68
Open:1.68
Low:1.60
Close:1.69
52wk High:10.99
52wk Low:1.60
Shares:22.66M
Float Shares:15.77M
Volume Ratio:0.90
T/O Rate:5.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.11
PE(LYR):-0.09

Loading ...

Karyopharm Therapeutics Price Target Raised to $16.00/Share From $8.00 by Piper Sandler

Dow Jones
·
Apr 28

Karyopharm price target raised to $16 from $8 at Piper Sandler

TIPRANKS
·
Apr 27

U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global

Reuters
·
Apr 27

Karyopharm Therapeutics Inc : Piper Sandler Raises Target Price to $16 From $8

THOMSON REUTERS
·
Apr 27

Karyopharm Phase 3 SENTRY myelofibrosis trial results set for ASCO late-breaking oral presentation

Reuters
·
Apr 21

Karyopharm publishes corporate presentation highlighting Phase 3 selinexor readouts in myelofibrosis

Reuters
·
Apr 16

RBC Capital Adjusts Karyopharm Therapeutics PT to $16 From $23, Maintains Outperform Rating

MT Newswires Live
·
Apr 07

Karyopharm Therapeutics Price Target Cut to $8.00/Share From $12.00 by Piper Sandler

Dow Jones
·
Mar 31

Karyopharm Therapeutics Inc : Piper Sandler Cuts Target Price to $8 From $12

THOMSON REUTERS
·
Mar 30

Karyopharm Therapeutics sells 1,030,354 shares at $6.785; gross proceeds rise to about $30 million in RA Capital private placement

Reuters
·
Mar 27

BUZZ-Street View: Karyopharm's cancer drug trial results limit regulatory odds

Reuters
·
Mar 25

Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 25

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
Mar 25

Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark

Benzinga
·
Mar 25

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Mar 24

Karyopharm Therapeutics Shares Reverse Course; NOW Down 10% Premarket

THOMSON REUTERS
·
Mar 24

Karyopharm Therapeutics Shares up 16% Premarket After Co's Blood Cancer Drug Meets One of Two Main Goals in Late‑Stage Study

THOMSON REUTERS
·
Mar 24

Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study

Reuters
·
Mar 24

Karyopharm’s Phase 3 SENTRY trial meets first co-primary endpoint

TIPRANKS
·
Mar 24

Karyopharm prices USD 30 million private placement with RA Capital

Reuters
·
Mar 24